Cell No. : Cell Name
RCB0526 : Jyg-MC(A)
update : 2022/12/21
|
| Comment | murine mammary tumor cell lines. High level MMTV producer line. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Morimoto, Junji
|
| Originator |
Morimoto, Junji
|
| Year of deposit |
1990
|
| Animal |
_mouse
< Mammals
|
| Strain name |
JYG
|
| Gender |
Female
|
| Tissue |
mammary
|
| Disease name |
mammary tumor
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
lung, liver,spleen
|
| Classification |
cancer
|
| Year of origin |
1987
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_H216
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| SSLP(mouse) |
|
OK
|
| Isozyme |
|
LD, NP, G6PD
|
| Chromosome mode |
|
38-126(50) : /39(7),40(11),41(4),55(1),58(2),59(1)/
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
9
|
| User's Publication |
8
|
| Reference |
|
979
Shibata MA, Ambati J, Shibata E, Albuquerque RJ, Morimoto J, Ito Y, Otsuki Y.
The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model
BMC Med
2010
8:69
PubMed ID: 21047425
|
|
986
Shibata MA, Shibata E, Morimoto J, Eid NA, Tanaka Y, Watanabe M, Otsuki Y.
An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging
Anticancer Res
2009
29(11):4389-95
PubMed ID: 20032383
|
|
978
Shibata MA, Morimoto J, Shibata E, Otsuki Y.
Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model
Cancer Gene Ther
2008
15(12):776-86
PubMed ID: 18654613
DOI: 10.1038/cgt.2008.43
|
|
974
Shibata MA, Morimoto J, Akamatsu K, Otsuki Y.
Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses
Med Mol Morphol
2008
41(1):34-43
PubMed ID: 18470679
DOI: 10.1007/s00795-007-0388-1
|
|
975
Shibata MA, Morimoto J, Doi H, Morishima S, Naka M, Otsuki Y.
Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis
Cancer Gene Ther
2007
14(3):268-78
PubMed ID: 17096028
DOI: 10.1038/sj.cgt.7701009
|
|
1004
Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y.
Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer
Med Electron Microsc
2004
37(4):216-24
PubMed ID: 15614446
DOI: 10.1007/s00795-004-0247-2
|
|
1001
Shibata MA, Morimoto J, Otsuki Y.
Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation
Cancer Gene Ther
2002
9(1):16-27
PubMed ID: 11916241
DOI: 10.1038/sj.cgt.7700415
|
|
1432
Morimoto J, Imai S, Haga S, Iwai Y, Iwai M, Hiroishi S, Miyashita N, Moriwaki K, Hosick, H L
New murine mammary tumor cell lines.
In Vitro Cell Dev Biol
1991
27A:349-51
PubMed ID: 2071538
DOI: 10.1007/BF02630952
|
|
1003
Kiyozuka Y, Asai A, Senzaki H, Uemura Y, Nakashima A, Morimoto J, Matsuzawa A, Tsubura A.
Telomere length, telomerase activity and telomerase RNA expression during mouse mammary tumor progression
Int J Mol Med
1988
2(4):437-44
PubMed ID: 9857231
DOI: 10.3892/ijmm.2.4.437
|
| User's Publication |
|
12491
Seo I, Cho JH, Lee MH, Park WJ, Kwon SY, Lee JH.
Clinical and Prognostic Value of Human Mammary Tumor Virus in Korean Patients with Breast Carcinoma
Ann Clin Lab Sci
2019
49(2):171-174
PubMed ID: 31028060
|
|
10266
San TH, Fujisawa M, Fushimi S, Yoshimura T, Ohara T, Soe L, Min NW, Kyaw O, Yang X, Matsukawa A.
Low prevalence of human mammary tumor virus (HMTV) in breast cancer patients from Myanmar.
Infect. Agents Cancer
2017
12:20
PubMed ID: 28413435
DOI: 10.1186/s13027-017-0130-0
|
|
14650
akano N, Tsuchiya Y, Kako K, Umezaki K, Sano K, Ikeno S, Otsuka E, Shigeta M, Nakagawa A, Sakata N, Itoh F, Nakano Y, Iemura SI, van Dinther M, Natsume T, Ten Dijke P, Itoh S.
TMED10 Protein Interferes with Transforming Growth Factor (TGF)-β Signaling by Disrupting TGF-β Receptor Complex Formation
J Biol Chem
2017
292(10):4099-4112.
PubMed ID: 28115518
DOI: 10.1074/jbc.M116.769109
|
|
14659
Okita Y, Kimura M, Xie R, Chen C, Shen LT, Kojima Y, Suzuki H, Muratani M, Saitoh M, Semba K, Heldin CH, Kato M.
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Sci Signal
2017
10(474):eaak9397
PubMed ID: 28400538
DOI: 10.1126/scisignal.aak9397
|
|
7147
Hiraga T, Ito S, Nakamura H.
EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation.
Int. J. Cancer
2016
138:1698-708
PubMed ID: 26576938
DOI: 10.1002/ijc.29921
|
|
8619
Lee TL, Li Y, Alba D, Vong QP, Wu SM, Baxendale V, Rennert OM, Lau YF, Chan WY.
Developmental staging of male murine embryonic gonad by SAGE analysis.
J Genet Genomics
2009
36:215-27
PubMed ID: 19376482
DOI: 10.1016/S1673-8527(08)60109-5
|
|
3952
Akatsu T, Ono K, Katayama Y, Tamura T, Nishikawa M, Kugai N, Yamamoto M, Nagata N.
The mouse mammary tumor cell line, MMT060562, produces prostaglandin E2 and leukemia inhibitory factor and supports osteoclast formation in vitro via a stromal cell-dependent pathway.
J Bone Miner Res
1998
13(3):400-8
PubMed ID: 9525340
DOI: 10.1359/jbmr.1998.13.3.400
|
|
18041
Ding Y, Tan W, Hu R, Chen W, Hou Y.
Construction of a novel fusion protein harboring mouse interferon gamma and epidermal growth factor receptor binding domain and enhancement of its antitumor activity
Sci China C Life Sci
1997
40(3):293-300
PubMed ID: 18726330
DOI: 10.1007/BF02879090
|
Back
Top
CELL BANK Website